GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Santen Pharmaceutical Co Ltd (OTCPK:SNPHF) » Definitions » Cash And Cash Equivalents

Santen Pharmaceutical Co (Santen Pharmaceutical Co) Cash And Cash Equivalents : $631 Mil (As of Mar. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Santen Pharmaceutical Co Cash And Cash Equivalents?

Santen Pharmaceutical Co's quarterly cash and cash equivalents increased from Sep. 2023 ($437.81 Mil) to Dec. 2023 ($569.73 Mil) and increased from Dec. 2023 ($569.73 Mil) to Mar. 2024 ($631.31 Mil).

Santen Pharmaceutical Co's annual cash and cash equivalents declined from Mar. 2022 ($700.08 Mil) to Mar. 2023 ($433.20 Mil) but then increased from Mar. 2023 ($433.20 Mil) to Mar. 2024 ($631.31 Mil).


Santen Pharmaceutical Co Cash And Cash Equivalents Historical Data

The historical data trend for Santen Pharmaceutical Co's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Santen Pharmaceutical Co Cash And Cash Equivalents Chart

Santen Pharmaceutical Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cash And Cash Equivalents
Get a 7-Day Free Trial Premium Member Only Premium Member Only 849.19 578.55 700.08 433.20 631.31

Santen Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash And Cash Equivalents Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 433.20 321.95 437.81 569.73 631.31

Santen Pharmaceutical Co Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.


Santen Pharmaceutical Co  (OTCPK:SNPHF) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


Santen Pharmaceutical Co Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Santen Pharmaceutical Co's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.


Santen Pharmaceutical Co (Santen Pharmaceutical Co) Business Description

Traded in Other Exchanges
Address
Grand Front Osaka Tower A, 4-20 Ofuka-cho, Kita-ku, Osaka, JPN, 530-8552
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company reports two primary operating segments: prescription ophthalmic pharmaceuticals and other. The pharmaceuticals segment includes over-the-counter pharmaceuticals, while the other segment includes medical devices. The vast majority of Santen's revenue is derived from its prescription ophthalmic pharmaceuticals segment, which manufactures and distributes prescription and OTC pharmaceuticals. Most of Santen's sales are generated in Japan, followed by other Asian countries.

Santen Pharmaceutical Co (Santen Pharmaceutical Co) Headlines

From GuruFocus

Matthews Japan Fund 1st-Quarter Commentary

By Sydnee Gatewood Sydnee Gatewood 04-23-2020

Matthews Japan Fund Comments on Santen Pharmaceutical

By Sydnee Gatewood Sydnee Gatewood 04-23-2020